

RECEIVED
CENTRAL FAX CENTER

FEB 10 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Tsvee LAPIDOT et al.

Art Unit: 1632

Application No.: 09/744,654

Conf. No. 2645

Examiner: A. M. S. WEHBE

Filed: January 29, 2001

Washington, D.C.

For: HEMATOPOIETIC CELL COMPOSITION FOR USE IN TRANSPLANTATION

Atty.'s Docket: LAPIDOT2

Date: February 10, 2006

VIA TELEFACSIMILE

THE COMMISSIONER OF PATENTS
U.S. Patent and Trademark Office
Randolph Building, Mail Stop AF
401 Dulany Street
Alexandria, VA 22314

Sir:

Transmitted herewith is a ☐ Amendment ☒ Supplemental Amendment
in the above-identified application.

☒ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.☒ No additional fee is required.☐ The fee has been calculated as shown below.

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 6	MINUS **	52	0
INDEP.	* 2	MINUS ***	9	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 25	\$
x 100	\$
+ 180	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 50	\$
x 200	\$
+ 360	\$
TOTAL	
	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
Response Filed Within
☐ First - \$ 60.00
☐ Second - \$ 225.00
☐ Third - \$ 510.00
☐ Fourth - \$ 795.00
 Month After Time Period Set


Other Than Small Entity
Response Filed Within
☐ First - \$ 120.00
☐ Second - \$ 450.00
☐ Third - \$ 1020.00
☐ Fourth - \$ 1590.00
 Month After Time Period Set

☐ Less fees (\$) already paid for ___ month(s) extension of time on _____.☐ Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.☐ A check in the amount of \$ _____ is attached (check no.).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 
 Roger L. Browdy
 Registration No. 25,618

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

FEB 10 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: LAPIDOT2

In re Application of:)	Conf. No.: 2645
)	
Tsvee LAPIDOT et al)	Art Unit: 1632
)	
Appln. No.: 09/744,654)	Examiner: A. Wehbe
)	
Filed: January 29, 2001)	Washington, D.C.
)	
For: HEMATOPOIETIC CELL)	February 10, 2006
COMPOSITION FOR USE IN)	
TRANSPLANTATION)	VIA TELEFACSIMILE

SUPPLEMENTAL AMENDMENT

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop AF
401 Dulany Street
Alexandria, VA 22314

Sir:

In response to the Office Action of July 28, 2005,
and supplementing applicant's response of December 28, 2005,
please further amend as follows:

Amendments to the Claims are reflected in the
listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.